Green Cross Corp
KRX:006280

Watchlist Manager
Green Cross Corp Logo
Green Cross Corp
KRX:006280
Watchlist
Price: 140 200 KRW -4.5%
Market Cap: 1.6T KRW
Have any thoughts about
Green Cross Corp?
Write Note

EV/EBITDA
Enterprise Value to EBITDA

22.5
Current
14.7
Median
4.3
Industry
Higher than median
Higher than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
22.5
=
Enterprise Value
2.4T KRW
/
EBITDA
105.9B KRW
All Countries
Close
Market Cap EV/EBITDA
KR
Green Cross Corp
KRX:006280
1.6T KRW 22.5
FR
Pharnext SCA
OTC:PNEXF
6T USD -216 796.7
US
Abbvie Inc
NYSE:ABBV
301B USD 14.8
US
Amgen Inc
NASDAQ:AMGN
162B USD 17.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
127.5B USD 26.9
US
Gilead Sciences Inc
NASDAQ:GILD
115.4B USD 10.2
US
Epizyme Inc
F:EPE
94.1B EUR -521.2
AU
CSL Ltd
ASX:CSL
138B AUD 20.9
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
88.6B USD 17.5
US
Seagen Inc
F:SGT
39.3B EUR -59.5
NL
argenx SE
XBRU:ARGX
34.1B EUR -104.5
EBITDA Growth
KR
Green Cross Corp
KRX:006280
Average EV/EBITDA: 18.6
22.5
78%
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -216 796.7 N/A
US
Abbvie Inc
NYSE:ABBV
14.8
28%
US
Amgen Inc
NASDAQ:AMGN
17.8
63%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.9
38%
US
Gilead Sciences Inc
NASDAQ:GILD
10.2
12%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -521.2 N/A
AU
CSL Ltd
ASX:CSL
20.9
42%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.5
46%
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.5 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -104.5 N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
16.9
2-Years Forward
EV/EBITDA
13.7
3-Years Forward
EV/EBITDA
12.2

See Also

Discover More